Last reviewed · How we verify
Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin: A Multicenter, Randomized Controlled Study
The researchers collected untreated H. pylori positive patients from outpatient clinics. Subjects were randomly assigned to receive either 14 days of bismuth quadruple therapy with cefuroxime and tetracycline or 14 days of bismuth quadruple therapy with cefuroxime and levofloxacin for Helicobacter pylori eradication. After 6 weeks of treatment, subjects underwent another 13C urea breath test. Eradication rates, adverse reaction rates and patient compliance were calculated.
Details
| Lead sponsor | Qilu Hospital of Shandong University |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 248 |
| Start date | 2024-04 |
| Completion | 2024-12 |
Conditions
- Helicobacter Pylori Infection
Interventions
- 14-day bismuth quadruple regimen containing cefuroxime and tetracycline
- 14-day bismuth quadruple regimen containing cefuroxime and levofloxacin
Primary outcomes
- Eradication rate — immediately after the procedure
Both intention to treat (ITT) and per-protocol (PP) analyses will be used for the assessment of the eradication rates of Helicobacter pylori infections in two groups.
Countries
China